Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
29 févr. 2024 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
25 janv. 2024 20h58 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
04 déc. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
07 juin 2023 09h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,...